200.00
+0.50%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CellaVision
Its shares trade on Nasdaq Stockholm under the ticker CEVI.ST. It has been listed since 28 May 2007. In the fiscal year to 31 December 2025, it reported revenue of SEK 759.0m and net income of SEK 153.1m. At that date it held total assets of SEK 1.09bn and shareholders' equity of SEK 887.6m.
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 28 May 2007
- Employees
- 177
- Website
- cellavision.com ↗
Leadership
Pay as last reported
- Mr. Mikael WorningIndependent Chairman of the BoardSEK 800,000
- Mr. Simon OestergaardPresident, Chief Executive OfficerSEK 6.6m
- Ms. Monica JoenssonInterim Chief Financial Officer
- Mr. Urban StrindloevVice President - Global Sales
- Ms. Elin BredbergVice President of Human Resources
- Mr. Adam MorellVice President - Devices & Software Division, since 2021
- Ms. Charlotte OomVice President - Quality, Clinical and Regulatory Affairs
- Mr. Julien VeyssyVice President - Reagents Division
- Mr. Peter WilsonVice President - Global Marketing & Business Development, since 2024
- Dr. Christer FahraeusDirector, Founder, since 1998SEK 285,000
- Mr. Emil HjalmarssonDirector
- Mr. Kent StrahlenDirector, Employee Representative
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 52
- Social
- 55
- Governance
- 42
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Technological Expertise: CellaVision AB has built a strong reputation in the market for its advanced technologies in digital microscopy and image analysis.
- High Quality Products: The company offers high-quality automated hematology analyzers and related software solutions, ensuring accuracy and reliability for its customers.
- Strong Market Presence: CellaVision AB has established a dominant position in the global hematology market, providing innovative solutions to healthcare institutions worldwide.
Weaknesses
- Limited Product Portfolio: The company's product portfolio predominantly focuses on hematology analysis, which leaves it vulnerable to market fluctuations and lack of diversification.
- Dependence on Key Customers: CellaVision AB relies on a few major customers for a significant portion of its revenue, exposing it to potential risks if these relationships deteriorate.
- Intense Competition: The industry is highly competitive, with several global players vying for market share. CellaVision AB needs to continuously innovate and adapt to maintain its competitive edge.
Opportunities
- Growing Healthcare Market: The increasing demand for efficient and advanced hematology analyzers presents an opportunity for CellaVision AB to expand its customer base.
- Emerging Markets: The company can explore untapped markets in developing countries where the adoption of automated hematology analyzers is on the rise.
- Technological Advancements: Continual advancements in imaging and analysis technologies open doors for CellaVision AB to develop innovative solutions and capture new market segments.
Threats
- Regulatory Challenges: Changing regulations and compliance requirements in the healthcare industry may pose challenges for CellaVision AB, leading to increased costs and restricted market access.
- Economic Volatility: Uncertain economic conditions could impact healthcare budgets, potentially reducing the demand for CellaVision AB's products.
- Technological Obsolescence: Rapid technological advancements could render current products obsolete, necessitating constant investment in research and development to stay ahead.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.